Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm<sup>3</sup>: A Post Hoc Analysis from the ANANKE Study.

Gianenrico SennaMaria AlianiElena AltieriPietro BraccialeLuisa BrussinoMaria Filomena CaiaffaPaolo CameliGiorgio Walter CanonicaCristiano CarusoMaria D'AmatoFausto De MicheleStefano Del GiaccoFederico Raimondi Francesco Menzella Girolamo Pelaia Rogliani PaolaMicaela RomagnoliPietro SchinoJan Walter SchroederAlessandra VultaggioSara RizzoliAlessandro ZulloSilvia BoarinoMarilena PalmisanoAlessandra Rossi Gianfranco VitielloStefano Centanni

Published in: Journal of asthma and allergy (2022)

At baseline, apart from lower severe exacerbation rate, the BEC 300-450 cells/mm<sup>3</sup> subset of patients is comparable to the total population prescribed with benralizumab. In this real-life study, benralizumab is as effective in BEC 300-450 patients as in the total population.

Keyphrases

end stage renal disease
induced apoptosis
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
cell cycle arrest
cell death
signaling pathway
oxidative stress
endoplasmic reticulum stress
patient reported